This preview is private. Enter the access code provided in your invitation email.
That code isn't right — please check your invitation email.
Demo access code: NQ2026 — in production, codes are issued per investor and expire on your schedule.
Concept preview
NovaQuest Presentation System · Proposed for the 2026 AGM
Last year, deck slides were lifted into the video as-is — and the dense ones were unreadable on screen. This preview shows the fix: design each page once, in a format built for all three jobs.
Fund V · Ryan Wooten, Managing Director
Six drug approvals since the last AGM
Drag to compare: the same Fund V content, last year vs. the proposed format.
Foundation
Every color and typeface below already lives on novaquest.com — the system just commits to them. One palette, two typefaces, one accent. Applied identically in PowerPoint, print, and video.
#003D7E#5292CB#66727C#DCE2E8#D26A20Ember is the single accent: the NovaQuest datapoint, the key number, the "look here." It replaces last year's red circles — and it can only appear once per page, so it always means something.
Merriweather 900
Open Sans — body, labels, chart text. Aa Bb Cc 0123456789
Both are free Google Fonts, so they render identically in PowerPoint, on the web, and in video. Calibri, Cambria, and Trajan-as-body-text retire; Trajan remains in the logo only.
The format in action
Real content from December's AGM. Toggle each page between Deck page (what investors print and read) and Video zone (what I lift straight into the edit) — then press Play to see the animation build investors would see on screen.
NovaQuest Track Record · Michael Bologna, Partner & CIO
Clinical success 30 points above the industry
Briefing — spoken in the video, read in the deck
To date, NovaQuest has supported 88 Phase 3 or pivotal studies across Funds III–VI. Of those with known outcomes, 89% were successful — they demonstrated clinical efficacy and safety in their primary endpoints in support of regulatory approval. The industry average is 55–60%.
That clinical success translates into a historical average of 82% of assets receiving regulatory approval — against an industry average of 57%.
To date, 27 products supported by NovaQuest have been approved or are pending approval — NovaQuest's impact on both the industry and on patients.
This 16:9 zone is lifted into the video unchanged — the Play animation is the build investors see on screen.
NovaQuest Overview · Patrick Jordan, Managing Partner
15 years standalone. $2.6B raised across five funds. 1
Briefing — spoken in the video, read in the deck
NovaQuest has been investing as a standalone firm for 15 years, after 10 years as the internal investing group of Quintiles — now IQVIA. Since spinning out in 2010, we have raised more than $2.6 billion of capital across five funds.
We are premarketing Animal Health Opportunities Fund II now, targeting a 2026 fund launch — the sixth fund on this platform.
This 16:9 zone is lifted into the video unchanged — the Play animation is the build investors see on screen.
Fund V Update · Ryan Wooten, Managing Director
Fund V: 22 investments, six approvals since last AGM
Briefing — spoken in the video, read in the deck
I'm pleased to present the highlights for our 2017 vintage, $1.16 billion Fund V.
The fund comprises 22 investments, four of which have been fully or substantially realized to date. Investment sizes range from $10 million to $150 million, with an average of about $50 million — significant diversification in asset type and investment level.
Since Q4 2024, the portfolio has celebrated six drug approvals across various indications and presentations, with one more product filed and awaiting approval. One restructuring closed in that period — Hansa Biopharma — resulting in increased potential yield for NovaQuest.
This 16:9 zone is lifted into the video unchanged — the Play animation is the build investors see on screen.
Animal Health · Brian Axe, Partner
A market most investors overlook
Estimated global animal health market 1
Briefing — spoken in the video, read in the deck
Broadly defined, the animal health industry includes all products and services that promote the health and wellness of both companion and production animals — an estimated $350 billion market.
Funding innovation in animal health remains a challenge: only 6% of an estimated 600 start-ups found funding in 2025. NovaQuest is one of the only investors with a core focus on science and innovation in the fastest-growing sectors — and we were part of that funding solution.
Strong macro tailwinds remain: the rise in pet ownership and the humanization of pets, and the need for a clean, efficient, and sustainable supply of protein essential to feed an estimated 10 billion people by 2050.
This 16:9 zone is lifted into the video unchanged — the Play animation is the build investors see on screen.
Delivery, next year
Last year meant an emailed PDF, a separate Vimeo password, and manually revoking access afterward. Next year, investors get a single URL — this page you're on is the working proof.
Per-investor or shared codes, expiring whenever NovaQuest decides — no more changing the Vimeo password and hoping.
The film embeds beside the page-by-page deck reader — investors watch, read, or print without juggling attachments.
Every page's video zone lifts into the edit; every page's notes become the teleprompter script. No redesign between formats.